Amneal Pharmaceuticals (AMRX) Depreciation & Amortization (CF) (2017 - 2018)

Amneal Pharmaceuticals' Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $18.6 million for Q4 2018.

• On a quarterly basis, Depreciation & Amortization (CF) rose 56.19% year-over-year to $18.6 million in Q4 2018; TTM through Sep 2019 was $18.6 million, a 58.38% decrease from a year earlier, with the FY2025 full-year figure at $57.3 million, down 8.47% from the prior year.
• Depreciation & Amortization (CF) improved to $18.6 million in Q4 2018 per AMRX's latest filing, from $17.4 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $18.6 million in Q4 2018 and bottomed at $9.6 million in Q2 2017.